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A B S T R A C T  
Background: N-Acetylcysteine and 3% hypertonic saline are being used effectively for sputum clearance in chronic cases of 
bronchiectasis for quite some time. However, their use in acute condition of the disease seems to be underexplored. The objective of 
our study is to compare the role of nebulized N-acetylcysteine and 3% hypertonic saline in clearing the airway in patients with acute 
exacerbation of bronchiectasis. 
Material and Methods: A total of 136 confirmed cases of bronchiectasis were enrolled in this study. This randomized controlled trial 
was done in chest ward of Nishtar Hospital Multan from January 2015 to March 2017. Sampling was done by non-probability 
consecutive sampling and patients were divided into two groups A and B by lottery method. Verbal informed consent was taken from 
all participants. Group A participants received nebulization of N acetylcysteine mixed in normal saline for ten minutes, while group B 
participants were nebulized with 10ml of 3% hypertonic saline for ten minutes. Group B was active control group in the study. Data 
was collected on pre-designed Proforma, and analyzed by SPSS version 22. Numerical variables such as saturation, weight of 
sputum, age and blood pressure was analyzed by using t test. These were considered significant if the p value was equal or less 
than 0 .05. For qualitative variables chi square test was applied. 
Results: The mean O2 saturation of Group A, before and after treatment, was 92.11±3.07% and 94.47±2.18%, respectively. The 
difference was statistically significant (p value =0.001). The sputum weight of Group A, before and after treatment, was 2.63±2.39 g 
and 7.41±1.38 g, respectively. The difference was statistically significant (p value =0.001). The frequency of rhonchi of Group A, 
before and after treatment, was 52% and 76%, respectively. The difference was statistically significant (p value =0.003). While, for 
Group B, the mean O2 saturation, before and after treatment, was 92.36±3.13% and 93.49±2.27%, respectively. The difference was 
statistically significant (p value =0.012). The sputum weight, before and after treatment, was 3.11±2.01 g and 5.56±1.02 g, 
respectively. The frequency of rhonchi, before and after treatment, was 45% and 74% respectively. Again, the difference was 
statistically significant. 
Conclusion: Both nebulized N-acetylcysteine and 3% hypertonic saline cause airway clearance by enhancing sputum expectoration 
in patients with acute exacerbation of bronchiectasis equally. Both these agents also improve oxygen saturation in acute 
exacerbation of bronchiectasis significantly. 
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I n t r o d u c t i o n  
N-Acetylcysteine is a mucolator and a drug with 
antioxidant qualities.  Both these qualities make it suitable 
for the treatment of chronic respiratory diseases, because 
there is excessive production of thick mucus. Large 
amount of mucus production causes repeated infections, 
difficulty in breathing, excessive cough and other 
symptoms, and this can be treated with mucolator 
qualities of N-acetylcysteine. Oxidative process has a 
major role in pathophysiology of many chronic respiratory 
diseases, and N-acetylcysteine reduces oxidant toxins.1 
Long term use of N-acetylcysteine has good safety profile 
with no major side effects.  Serious side effects are very 
rare.2,3 In many chronic respiratory diseases, clinical trials 
of N-acetylcysteine have been carried out and results 
have shown that it relieved symptoms and improved 
quality of life.4,5 
 
Hypertonic saline is salty water and is found to be 
beneficial when nebulized in many chronic respiratory 
diseases. It has various mechanisms of action; it 
produces osmotic pressure which causes addition of 
water to surface of airway and this rheological quality 
makes the mucus suitable for clearance through cough. It 
also causes disruption of bond in mucus gel and thus 
reduces viscosity and elasticity by reducing cross linking. 
It is said to have shown some anti-inflammatory 
properties as well by reducing the formation of bio-film by 
organisms. Hypertonic saline increases the levels of thiols 
and behaves as anti-oxidants.6,7 In nebulized form, it is 
well tolerated and no adverse reactions are reported.8 In 
many chronic respiratory diseases, efficacy of hypertonic 
saline has been evaluated and is said to have shown 
improvement in quality of life by relieving symptoms.9,10 
 
Although the role of both these agents is well established 
in clearing airway during chronic bronchiectasis, but their 
action in acute exacerbation of the same disease seems 
to be underexplored.  To the best of our knowledge no 
study has been carried out in this regard so far.  
Therefore, we compared the efficacy of both N-
Acetylcysteine and 3% hypertonic solution in clearing the 
airways in acute exacerbation of the disease and hope to 
provide some evidence-based data regarding their 
usefulness. 
M a t e r i a l  a n d  M e t h o d s  
After approval from Ethical Committee of Nishtar Hospital 
Multan, a total of 136 participants were recruited for the 
study.  All the participants were diagnosed cases of acute 
exacerbation of bronchiectasis and were admitted in the 
Chest Ward of Nishtar Hospital Multan from January 2015 
to March 2017 either through Emergency or Outpatient 
Departments. Acute exacerbation of bronchiectasis was 
defined as worsening of shortness of breath, fever or 
increased production of sputum. Sample size was 
calculated by taking a reference study with power of study 
80 and confidence interval 95% in which sputum 
expectoration was 2.65 +3.47 g and after treatment was 
7.5 +6.29 g by using software www.openepi.com.11 
 
Sampling was done by non-probability consecutive 
sampling and patients were divided into two groups A and 
B by lottery method. Verbal informed consent was 
obtained from all participants of the study. Group A were 
given standard medical treatment for bronchiectasis with 
nebulization of N acetylcysteine mixed in normal saline for 
ten minutes while group B participants were nebulized 
with 10ml of 3% hypertonic saline also for ten minutes. 
Group B in the study was considered as active control 
group. 
 
A focused history was taken from all the patients and 
detailed examination was done. The demographic 
information and the variables to be studied were recorded 
by the investigators on self-designed proforma. 
Demographic variables included age, gender, blood 
pressure, smoking status, educational status, residential 
area and diabetes. 
 
Chest was auscultated for wheeze, or rhonchi and 
findings were recorded.  Blood samples were drawn and 
baseline investigations were done. Forty minutes before 
nebulization sputum samples were collected from every 
patient and their weight recorded. After that nebulization 
with assigned drug was started for each patient in both 
the groups. Patients of both groups were nebulized three 
times in 24 hours. After 24 hours, sputum was collected 
again in calibrated containers and its weight measured. 
Oxygen saturation was also measured. 
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Data was analyzed by SPSS version 22. Numerical 
variables such as age, blood pressure, saturation, weight 
of sputum, were analyzed by t-test. These were 
considered significant if the p value was equal or less 
than 0.05. Percentages of qualitative variables were 
calculated and chi square test was applied to test their 
significance. 
 
R e s u l t s  
Table I presents the details of demographic data. There 
were more males affected by the acute exacerbation than 
females and more patients belonged to rural than urban 
areas. The percentage of smokers was greater in group A 
and those of non-smokers was greater in group B. 
Comparison of parameters pre- and post-nebulization is 
shown in Table II. Oxygen saturation improved after 
nebulization in both the groups (A and B) as apparent by 
the statistically significant difference of 0.001 and 0.012 
respectively. 
 
Sputum weight also increased after nebulization in both 
the groups significantly with p value of 0.001 in both the 
groups. Similar is the case with frequency of rhonchi 
which increased after nebulization with both the drugs 
significantly with p value of 0.003 and 0.001 in groups A 
and B respectively. 
 
Table I Demographic Characteristics of both groups 
Variables Group A 
n=68 
Group B 
n=68 
Mean Age (years) 38.89±2.57 46.07±5.12 
Mean Blood pressure  
(mm Hg) 
91.13±1.11 96.48±2.26 
Gender n (%) 
Male 37 (54.4%) 47 (69.1%) 
Female 31 (45.6%) 21 (30.9%) 
Smoking n (%) 
Yes 38 (55.9%) 27 (39.7%) 
No 30 (44.1%) 41 (60.3%) 
Education Status  n (%) 
Literate 41 (60.3%) 32 (47.1%) 
Illiterate 27 (39.7%) 36 (52.9%) 
Residential area  n (%) 
Rural 47 (69.1%) 41 (60.3%) 
Urban 21 (30.9%) 27 (39.7%) 
Diabetics n (%) 15 (22.1%) 10 (14.7%) 
 
Table II Comparison of parameters in both groups before and 
after treatment 
Variable Before Treatment After Treatment P-value 
Oxygen saturation (%) 
Group A  92.11±3.07 94.47±2.18 0.001 
Group B 92.36±3.13 93.49±2.27 0.012 
Sputum weight (g) 
Group A  2.63±2.39 7.41±1.38 0.001 
Group B 3.11±2.01 5.56±1.02 0.001 
Ronchi (%) 
Group A  52% 76% 0.003 
Group B 45% 74% 0.001 
 
 
D i s c u s s i o n  
Patients of both groups showed significant improvement 
after nebulization three times in 24 hours. Patients in both 
groups expectorated significantly greater amount of 
sputum post-nebulization thus improving symptoms. 
Effects of N-acetylcysteine in clearing airway and sputum 
expectoration have been observed in various studies. 
Outcomes of our study are consistent with most of the 
other researches. Hirsch and Kory demonstrated that 
nebulization with N-acetylcysteine caused thinning of 
sputum leading to increased expectoration.12 Kory et al 
reported increase sputum expectoration when N-
acetylcysteine was combined with a bronchodilator in 
patients with chronic bronchitis.13 Pavia et al reported 
significantly improved sputum expectoration after 
nebulization with hypertonic saline of 7.1%.14 However, N-
acetylcysteine when used in nebulization form for 
mechanically ventilated patients did not lead to significant 
improvement in airway clearance.15 
 
Improved airway clearance by mucolytic agents caused 
improved lung function and oxygen saturation by 
improving minimizing effects of atelectasis. Ueno O. et al. 
demonstrated that nebulization of N-acetylcysteine in 
obstructive lung disease caused improved oxygenation 
and hypercapnia was relieved. N-acetylcysteine also 
caused improved gaseous exchange after bronchospasm 
caused by methacholine challenge test.16 Hypertonic 
salines can be used to clear the airway by causing more 
hydration of the airway and electrostatic effects on 
respiratory secretions and also due to enhancing cough 
reflex and improved oxygenation.17 
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In a retrospective study, nebulization with hypertonic 
saline was used to treat acute exacerbation of cystic 
fibrosis, after which it caused bronchospasm.18 In a study 
by Pappová et al showed that nebulization with N-
acetylcysteine caused bronchospasm by increasing 
airway reactivity.19 Similarly, in our study nebulization with 
both 3% hypertonic saline and N-acetylcysteine caused 
increased airway reactivity and rhonchi. We recommend 
further research in this regard. Limitations of the study 
were reduced sample size, one-center trial and no follow 
up after discharge. 
 
C o n c l u s i o n  
Nebulization with both N-acetylcysteine and 3% 
hypertonic saline improves airway clearance by 
enhancing sputum expectoration in patients with acute 
exacerbation of bronchiectasis. Both these agents 
improve/increase oxygen saturation and post 
expectoration weight of sputum significantly. 
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